* Integra Lifesciences Holdings Corp IART.OQ IART.O is
expected to show a fall in quarterly revenue when it reports
results on February 22.
* The Princeton New Jersey-based company is expected to
report a
1.9% decrease in revenue to $397.95 million from $405.52 million
a year ago, according to the mean estimate from 10 analysts,
based on Refinitiv data. The company's guidance on January 10
2023, for the period ended December 31, was for revenue between
$397.00 million and $398.00 million.
* Refinitiv's mean analyst estimate for Integra
Lifesciences
Holdings Corp is for earnings of 90 cents per share. The
company's EPS guidance on October 26 2022, for the period ended
December 31, was between $0.87 and $0.91
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 9
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Integra
Lifesciences Holdings Corp is $58, above its last closing
price of $57.54.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.71 0.72 0.86 Beat 19.5
Jun. 30 2022 0.80 0.80 0.81 Beat 1.6
Mar. 31 2022 0.68 0.68 0.74 Beat 8.8
Dec. 31 2021 0.84 0.83 0.84 Beat 0.7
Sep. 0.72 0.72 0.86 Beat 18.7
30 2021
Jun. 30 2021 0.67 0.66 0.79 Beat 19.9
Mar. 31 2021 0.57 0.57 0.69 Beat 22
Dec. 31 2020 0.72 0.73 0.84 Beat 15.2
This summary was machine generated February 20 at 16:01 GMT.
All figures in US dollars unless otherwise stated